HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
SANORG 32701
structure given in first source
Also Known As:
SANORG-32701
Networked:
1
relevant articles (
1
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Carbohydrates: 22023
Polysaccharides: 15383
Oligosaccharides: 3566
SANORG 32701: 1
Related Diseases
1.
Thrombosis (Thrombus)
09/01/1996 - "
In the rat, SANORG 32701 potently inhibited thrombus formation induced on a silk thread in an arteriovenous shunt and in the vena cava.
"
09/01/1996 - "
SANORG 32701 inhibited the accretion of fibrinogen I 125 to a preformed thrombus in the rabbit jugular vein and significantly reduced thrombus growth occurring after electrical stimulation of the rabbit carotid artery.
"
09/01/1996 - "
In the rabbit, intravenous injection of SANORG 32701 enhanced tissue plasminogen activator (TPA)-induced thrombolysis, suggesting that concomitant use of SANORG 32701 during TPA therapy may be helpful in preventing thrombus accretion, thus facilitating clot lysis.
"
09/01/1996 - "
SANORG 32701 displayed antithrombotic activity by virtue of its potentiation of the anti-factor Xa activity of AT-III. It strongly inhibited thrombus formation in an experimental model of thromboplastin-induced venous thrombosis in rats (intravenously) and rabbits (subcutaneously) (ED50 values were 25.5 +/- 4.1 and 91 +/- 12.7 nmol/kg, respectively).
"
2.
Venous Thrombosis (Deep-Vein Thrombosis)
09/01/1996 - "
SANORG 32701 displayed antithrombotic activity by virtue of its potentiation of the anti-factor Xa activity of AT-III. It strongly inhibited thrombus formation in an experimental model of thromboplastin-induced venous thrombosis in rats (intravenously) and rabbits (subcutaneously) (ED50 values were 25.5 +/- 4.1 and 91 +/- 12.7 nmol/kg, respectively).
"
3.
Hemorrhage
09/01/1996 - "
Compared with standard heparin, SANORG 32701 (1000 nmol/kg IV) caused only minimal bleeding enhancement and exhibited a favorable antithrombotic activity/ bleeding risk ratio, therefore showing that it might be considered as a promising compound in the treatment and prevention of various thrombotic diseases.
"
Related Drugs and Biologics
1.
Tissue Plasminogen Activator (Alteplase)
2.
Silk
3.
Factor Xa (Coagulation Factor Xa)
4.
Thromboplastin (Tissue Factor)
5.
Heparin (Liquaemin)
6.
Fibrinogen (Factor I)
Related Therapies and Procedures
1.
Therapeutics
2.
Intravenous Injections